This company has been marked as potentially delisted and may not be actively trading. NASDAQ:FGEN FibroGen (FGEN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock About FibroGen Stock (NASDAQ:FGEN) Get FibroGen alerts:Sign Up Key Stats Today's Range$9.23▼$9.7550-Day Range$8.08▼$10.0452-Week Range$4.85▼$12.60Volume31,125 shsAverage Volume40,794 shsMarket Capitalization$39.57 millionP/E Ratio0.18Dividend YieldN/APrice Target$43.00Consensus RatingHold Company Overview FibroGen, Inc., headquartered in San Francisco, California, is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapies for serious unmet medical needs. Since its founding in 1993, the company has built a diversified portfolio encompassing small molecules and biologics that address anemia, fibrotic diseases and oncology. The company’s lead product, roxadustat, is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor designed to treat anemia in chronic kidney disease. Roxadustat has received regulatory approval in China, Japan and several other markets, and is being developed globally through strategic partnerships with Astellas Pharma and AstraZeneca. In addition to roxadustat, FibroGen is advancing pamrevlumab, a monoclonal antibody in late-stage trials for idiopathic pulmonary fibrosis and other fibrotic disorders, as well as early-stage oncology assets aimed at modifying the tumor microenvironment. FibroGen operates research and development centers across North America, Europe and Asia, leveraging both in-house expertise and external collaborations to drive clinical progress. The company’s global footprint enables efficient regulatory engagement and commercialization in multiple jurisdictions, from China’s rapidly growing pharmaceutical market to established regulatory regions such as the United States and Europe. Under the leadership of President and Chief Executive Officer Tom Neff, FibroGen emphasizes rigorous science and strategic partnerships to accelerate its pipeline. The management team combines biotech innovation with industry experience, steering the company through clinical milestones and regulatory approvals while seeking to bring transformative medicines to patients worldwide.AI Generated. May Contain Errors. Read More Receive FGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for FibroGen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FGEN Stock News HeadlinesKyntra Bio to Report Fourth Quarter and Full Year 2025 Financial ResultsMarch 9, 2026 | globenewswire.comBragar Eagel & Squire, P.C.March 7, 2026 | businesswire.comPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.May 24 at 1:00 AM | Porter & Company (Ad)Kyntra Bio to Participate in Upcoming Investor ConferencesFebruary 17, 2026 | markets.businessinsider.comFibroGen rebrands as Kyntra Bio, refocuses on oncologyJanuary 9, 2026 | theglobeandmail.comFibroGen stock rises after announcing rebrand to Kyntra BioJanuary 7, 2026 | investing.comFibroGen, Inc.: FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and MomentumJanuary 7, 2026 | finanznachrichten.deFibroGen, Inc. Rebrands to Kyntra Bio, Targeting Oncology and Rare Disease Therapeutics with New Nasdaq Trading Symbol "KYNB"January 7, 2026 | quiverquant.comQSee More Headlines FGEN Stock Analysis - Frequently Asked Questions How were FibroGen's earnings last quarter? FibroGen, Inc (NASDAQ:FGEN) issued its quarterly earnings data on Monday, November, 10th. The biopharmaceutical company reported ($1.61) earnings per share for the quarter, beating the consensus estimate of ($4.01) by $2.40. The biopharmaceutical company had revenue of $1.08 million for the quarter, compared to the consensus estimate of $1.64 million. Read the conference call transcript. When did FibroGen's stock split? FibroGen shares reverse split on Tuesday, June 17th 2025.The 1-25 reverse split was announced on Thursday, June 12th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 16th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did FibroGen IPO? FibroGen (FGEN) raised $142 million in an IPO on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $16.00-$19.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers. What other stocks do shareholders of FibroGen own? Based on aggregate information from My MarketBeat watchlists, some other companies that FibroGen investors own include Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR), The RMR Group (RMR), iShares Micro-Cap ETF (IWC) and AUO (AUOTY). Company Calendar Last Earnings11/10/2025Today5/24/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FGEN CIK921299 Webwww.fibrogen.com Phone(415) 978-1200Fax415-978-1902Employees570Year Founded1993Price Target and Rating Average Price Target for FibroGen$43.00 High Price Target$43.00 Low Price Target$43.00 Potential Upside/Downside+340.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)$53.48 Trailing P/E Ratio0.18 Forward P/E RatioN/A P/E GrowthN/ANet Income-$47.58 million Net Margins2,598.55% Pretax Margin-630.78% Return on EquityN/A Return on Assets-26.27% Debt Debt-to-Equity RatioN/A Current Ratio3.71 Quick Ratio3.60 Sales & Book Value Annual Sales$29.62 million Price / Sales1.34 Cash FlowN/A Price / Cash FlowN/A Book Value($50.89) per share Price / Book-0.19Miscellaneous Outstanding Shares4,050,000Free Float3,921,000Market Cap$39.57 million OptionableOptionable Beta0.77 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:FGEN) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredThe worst mistake you can make with the SpaceX IPOThe $1.75 trillion SpaceX IPO is generating massive hype - but history shows retail investors who pile in on d...Weiss Ratings | SponsoredYour $29.97 book is free todayBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroGen, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
